- Home
- FTDR vs KNSA Comparison
FTDR vs KNSA Comparison
Compare FTDR & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTDR | KNSA |
|---|---|---|
| Founded | 1971 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.5B |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FTDR | KNSA |
|---|---|---|
| Price | $64.20 | $46.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $64.00 | $55.29 |
| AVG Volume (30 Days) | 610.7K | ★ 611.0K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 13.62 | ★ 225.00 |
| EPS | ★ 3.42 | 0.75 |
| Revenue | ★ $2,093,000,000.00 | $677,564,000.00 |
| Revenue This Year | $5.97 | $38.01 |
| Revenue Next Year | $5.91 | $17.42 |
| P/E Ratio | ★ $18.67 | $62.61 |
| Revenue Growth | 13.56 | ★ 60.09 |
| 52 Week Low | $35.65 | $18.26 |
| 52 Week High | $70.77 | $49.12 |
Technical Indicators
Market Signals| Indicator | FTDR | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 55.38 | 56.42 |
| Support Level | $55.67 | $39.96 |
| Resistance Level | $69.78 | $48.29 |
| Average True Range (ATR) | 2.71 | 1.82 |
| MACD | -0.30 | -0.04 |
| Stochastic Oscillator | 39.65 | 78.35 |
Price Performance
Historical ComparisonAbout FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.